Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration of its business with 3M's Food Safety Division and the financial implications of this merger [1][3][4]. Company Overview - Neogen Corporation specializes in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. Class Action Details - The class action lawsuit is titled "Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation" and allows investors who purchased Neogen common stock between January 5, 2023, and June 3, 2025, to seek appointment as lead plaintiff by September 16, 2025 [1][7]. - The lawsuit alleges that Neogen's executives made false statements about the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3][4]. Financial Performance - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in fiscal year 2025 revenue and EBITDA guidance [4]. - In the third quarter of 2025, Neogen reported a loss of $11 million, a significant increase from a $2 million loss the previous year, with revenue declining by 3.4% to $221 million due to integration issues [5]. - On June 4, 2025, Neogen projected an EBITDA margin drop to the high teens from 22%, attributing this to elevated inventory write-offs, which led to a further decline in stock price by over 17% [6].

Core Insights - Neogen (NEOG) reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.08 per share, and down from $0.1 per share a year ago, representing an earnings surprise of -37.50% [1] - The company posted revenues of $225.46 million for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 1.90%, but down from $236.79 million year-over-year [2] - Neogen shares have declined approximately 55.4% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $207.35 million, and for the current fiscal year, it is $0.44 on revenues of $832.77 million [7] - The trend of estimate revisions for Neogen was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which Neogen belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Neogen's stock performance [5]

Financial Data and Key Metrics Changes - The fourth quarter revenues were $225 million, with core revenue down 2.9% for the quarter, impacted by foreign currency and discontinued products [19] - Gross margin in Q4 was 41.2%, affected by lower volume, elevated inventory write-offs, and production inefficiencies [23][24] - Adjusted net income for Q4 was $11 million, down from $22 million in the prior year quarter, primarily due to lower adjusted EBITDA [26] Business Line Data and Key Metrics Changes - Food Safety segment revenues were $162 million in Q4, down 3% year-over-year, with a core revenue decline of 1.3% [19] - Animal Safety segment revenues were $64 million, including a core revenue decline of 6.7% compared to the prior year quarter [20] - Genomics core revenue declined low single digits in Q4, reflecting a sequential improvement [20] Market Data and Key Metrics Changes - Core revenue growth in Europe was up mid single digits, while Asia Pacific was down mid single digits [21] - Latin America region saw a mid single digit decline on a core basis, with growth in some product lines offset by declines in others [22] - U.S. and Canada region experienced low single digit growth in food safety core revenue [22] Company Strategy and Development Direction - The company is focused on improving internal processes and managing through current market conditions to capitalize on future opportunities [17] - A targeted improvement plan has been released to manage the transition period effectively [17] - The company is prioritizing pathogen detection and has launched new products to enhance its offerings in the food safety market [10][19] Management's Comments on Operating Environment and Future Outlook - Management noted that end market conditions have worsened, particularly in food safety, due to inflation pressures on food producers [4][5] - The expectation is for revenue in fiscal 2026 to be between $820 million and $840 million, reflecting ongoing market challenges [29] - Management anticipates that gross margin will face headwinds from sample collection and tariffs, but expects improvements in the second half of the fiscal year [30] Other Important Information - The company completed the divestiture of its cleaners and disinfectants business, resulting in approximately $115 million in net proceeds [27] - Free cash flow in Q4 was roughly breakeven, with total capital expenditures declining to $16 million [28] - The company has successfully remediated two Sarbanes-Oxley material weaknesses [31] Q&A Session Summary Question: Why is this the right time to put out guidance with a new CEO? - Management indicated that the guidance reflects a business-as-usual approach and is intended to provide clarity on the upcoming year [37][38] Question: How much of a headwind is built for next year regarding tariffs? - Management confirmed that the $10 million tariff impact is the expected headwind for fiscal 2026 [41] Question: How does the company plan to grow above market despite consumer pressures? - Management highlighted regulatory opportunities and increased testing focus as key growth drivers [44][45] Question: What are the expectations for food safety industry growth? - Management expects food safety testing to grow at a lower rate than historical mid-single digits due to current market conditions [53][54] Question: What is the expected impact of divestitures on operating expenses? - Management noted that most costs associated with divested businesses will go directly with those businesses, with minimal stranded costs remaining [59][60]

NEW YORK, July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neogen Corporation ("Neogen Corporation" or the "Company") (NASDAQ: NEOG) of a class action securities lawsuit. WHAT'S NEXT? If you suffered a loss in Neogen Corporation during the relevant time frame, you have until September 16, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, yo ...

Financial Performance - Q4 FY25 revenue was $225.5 million, a decrease from $236.8 million in Q4 FY24[11] - Adjusted EBITDA for Q4 FY25 was $40.6 million, compared to $53.0 million in Q4 FY24, with a margin of 18.0% versus 22.4%[12] - Adjusted net income decreased to $11.3 million ($0.05 per share) in Q4 FY25 from $22.4 million ($0.10 per share) in Q4 FY24[13] - Core revenue growth in the Food Safety segment was (1.3)%, while the Animal Safety segment experienced a core revenue growth of (6.7)%[15] Balance Sheet and Capital Allocation - As of May 31, 2025, gross debt was $900 million and net debt was $771 million[17] - Pro forma net debt, after accounting for cash and equivalents, is $656 million with gross debt at $800 million[17] - Net proceeds from the Cleaners & Disinfectants divestiture were approximately $115 million, with $100 million allocated for debt paydown in Q1[19] FY26 Outlook - The company anticipates FY26 revenue to be between $820 million and $840 million[21] - Adjusted EBITDA is projected to be in the range of $165 million to $175 million[21] - Capital expenditures are estimated to be around $50 million, including approximately $35 million for integration-related expenses[21]

Exhibit 99.1 Neogen Announces Fourth-Quarter 2025 Results • Revenue of $225.5 million. • Net loss of $612.2 million due to non-cash goodwill impairment; $(2.82) per diluted share. • Adjusted Net Income 1 of $11.3 million; $0.05 per diluted share. • Adjusted EBITDA 1 of $40.6 million. "The softer end-market conditions continued in the fourth quarter, with elevated trade uncertainty and the cumulative effect of the last four years of inflation on food production," said John Adent, Neogen's President and Chief ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neogen Corporation ("Neogen Corporation" or the "Company") (NASDAQ: NEOG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neogen Corporation investors who were adversely affected by alleged securities fraud between January 5, 2023 and June 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/neogen ...

Group 1 - Neogen Corporation (NASDAQ: NEOG) is a specialized player in the food safety and animal safety markets [1] - The company is undergoing significant strategic changes to reshape its overall portfolio [1] - There is a growing focus on the company's strategic direction [1]

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the common stock of Neogen Corporation ("Neogen" or the "Company") (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025, inclusive. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of th ...

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration with 3M and the financial health of the company during the class period from January 5, 2023, to June 3, 2025 [1][3]. Company Overview - Neogen Corporation, along with its subsidiaries, specializes in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. Allegations of the Lawsuit - The lawsuit claims that Neogen's executives misrepresented the progress of the integration with 3M, leading investors to believe it was more successful than it was [3]. - The complaint states that when inefficiencies from the integration were disclosed, the executives downplayed these issues and assured investors of their commitment to resolving them [3]. Financial Performance - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in fiscal year 2025 revenue and EBITDA guidance [4]. - Following the announcement of its third quarter results on April 9, 2025, Neogen reported a loss of $11 million, a decline in revenue by 3.4% to $221 million, and a significant drop in stock price by 28% [5]. - On June 4, 2025, Neogen projected an EBITDA margin drop to the high teens from 22%, attributing this to elevated inventory write-offs, which led to a further stock price decline of over 17% [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Neogen common stock during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8][9].